Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Антиандрогенный эффект Ярины в клинической практике
Антиандрогенный эффект Ярины в клинической практике
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Прилепская В.Н. Контрацептивные гормоны в терапии и профилактике гинекологических заболеваний. В кн.: Практическая гинекология, под ред. В.И.Кулакова, В.Н.Прилепской. М.: МЕДпрессинформ, 2001; 465–82.
2. Azziz R, Carmina E, Sawaya ME. Idiopathic hirsutism. Endocr Rev 2000; 21: 347–62.
3. Gilling-Smith C. Hirsutism. Cur Obstet Gynaecol 2002; 12: 144–9.
4. Burkman RTJ. The role of oral contraceptives in the treаtment of hyperandrogenic disorders. Am J Med 1995; 98 (1A): 130S–136S.
5. Shulman LP. Safety and efficacy of a new oral contraceptive containing drospirenone. J Reprod Med 2002; 47(Suppl. 11): 981–4.
6. Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000; 62: 29–38.
7. Thorneycroft IH. Evolution of progestins. Focus on the novel progestin drosperinone. J Reprod Med 2002; 47 (Suppl. 11): 975–80.
8. Fuhrmann U, Krattenmacher R, Slater EP, Fritzmeier KH. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potencial. Contraception 1996; 54: 243–51.
9. van Vloten WA, van Haselen CW, van Zuuren EJ et al. The effect of two combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis 2002; 69 (Suppl. 4): 2–15.
10. Boschitsch E, Skarabis H, Wuttke W, Heithecker R. The acceptability of a novel oral contraceptive containing drospirenone and its effect on well-being. Eur J Contracept Reprod Health Care 2000; 5 (3): 34–40.
11. Huber J, Foidart JM, Wuttke W et al. Efficacy and tolerability of a monophasic oral contraceptive containing etinylestradiol and drospirenone. Eur J Contracept Reprod Health Care 2000; 14: 25–34.
12. Azziz R. The evaluation and management of hirsutism. Obstet Gynecol 2003; 3: 127–31.
13. Ajossa S, Guerriero S, Paoletti AM et al. The treatment of polycystic ovary syndrome. Minerva Ginecol 2004; 56: 15–26.
14. Daniels TL, Berga SL. Resistance of gonadotropin releasing hormone drive to sex steroid-induced suppression in hyperandrogenic anovulation. J Clin Endocrinol Metab 1997; 82 (12): 4179–83.
15. Shultz W. Hormonal contraception. 2nd ed. Berlin: Schering, 1996.
16. Cerel-Suhl SL, Yeager BF. Update on oral contraceptive pills. Am J Obstet Gynecol 1999; 179: 577–82.
17. Mastoracos G, Koliopoulos C, Creatsas G. Androgen and lipid profile in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives. Fertil Steril 2002; 77: 919–27.
18. McCartney, Eagleson CA, Marshall JC. Regulation of gonadotropin secretion: implication for polycystic ovary syndrome. Semin Reprod Med 2002; 20: 317–26.
19. Falsetti L, Gambera A, Tisi G. Efficacy of the combination ethinyl oestradiol and cyproterone acetate on endocrine, clinical and ultrasonografic profile in polycystic ovarian syndrome. Hum Reprod 2001; 16: 36–42.
20. Guido M, Romualdi D, Giuliani M et al. Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study. J Clin Endocrinol Metab 2004; 89 (6): 2817–23.
21. Batukan C, Muderis II. Efficacy of a new oral contraceptive containing drospirenone and ethinyl estradiol in the long-term treatment of hirsutism. Fertil Steril 2006; 85 (2): 436–40.
22. Heuser I, Deuschle M, Weber B et al. Increased activity of the hypothalamus-pituitary-adrenal system after treatment with the minralocorticoid receptor antagonist spironolactone. Psychoneuroendocrinology 2000; 25: 513–8.
23. Parsey KS, Pong A. An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen. Contraception 2000; 61: 105–11.
24. Прилепская В.Н., Назарова М.Н. Гормональная контрацепция. В кн.: Серов В.Н., Прилепская В.Н., Овсянникова Т.В. Гинекологическая эндокринология. М.: МЕДпрессинформ, 2004; 381–470.
25. Wild RA. Long-term health consequences of PCOS. Hum Reprod Update 2002; 8: 231–41.
26. Wiegratz I, Kuhl H. Long-cycle treatment with oral contraceptives. Drugs 2004; 64 (21): 1–16.
2. Azziz R, Carmina E, Sawaya ME. Idiopathic hirsutism. Endocr Rev 2000; 21: 347–62.
3. Gilling-Smith C. Hirsutism. Cur Obstet Gynaecol 2002; 12: 144–9.
4. Burkman RTJ. The role of oral contraceptives in the treаtment of hyperandrogenic disorders. Am J Med 1995; 98 (1A): 130S–136S.
5. Shulman LP. Safety and efficacy of a new oral contraceptive containing drospirenone. J Reprod Med 2002; 47(Suppl. 11): 981–4.
6. Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000; 62: 29–38.
7. Thorneycroft IH. Evolution of progestins. Focus on the novel progestin drosperinone. J Reprod Med 2002; 47 (Suppl. 11): 975–80.
8. Fuhrmann U, Krattenmacher R, Slater EP, Fritzmeier KH. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potencial. Contraception 1996; 54: 243–51.
9. van Vloten WA, van Haselen CW, van Zuuren EJ et al. The effect of two combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis 2002; 69 (Suppl. 4): 2–15.
10. Boschitsch E, Skarabis H, Wuttke W, Heithecker R. The acceptability of a novel oral contraceptive containing drospirenone and its effect on well-being. Eur J Contracept Reprod Health Care 2000; 5 (3): 34–40.
11. Huber J, Foidart JM, Wuttke W et al. Efficacy and tolerability of a monophasic oral contraceptive containing etinylestradiol and drospirenone. Eur J Contracept Reprod Health Care 2000; 14: 25–34.
12. Azziz R. The evaluation and management of hirsutism. Obstet Gynecol 2003; 3: 127–31.
13. Ajossa S, Guerriero S, Paoletti AM et al. The treatment of polycystic ovary syndrome. Minerva Ginecol 2004; 56: 15–26.
14. Daniels TL, Berga SL. Resistance of gonadotropin releasing hormone drive to sex steroid-induced suppression in hyperandrogenic anovulation. J Clin Endocrinol Metab 1997; 82 (12): 4179–83.
15. Shultz W. Hormonal contraception. 2nd ed. Berlin: Schering, 1996.
16. Cerel-Suhl SL, Yeager BF. Update on oral contraceptive pills. Am J Obstet Gynecol 1999; 179: 577–82.
17. Mastoracos G, Koliopoulos C, Creatsas G. Androgen and lipid profile in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives. Fertil Steril 2002; 77: 919–27.
18. McCartney, Eagleson CA, Marshall JC. Regulation of gonadotropin secretion: implication for polycystic ovary syndrome. Semin Reprod Med 2002; 20: 317–26.
19. Falsetti L, Gambera A, Tisi G. Efficacy of the combination ethinyl oestradiol and cyproterone acetate on endocrine, clinical and ultrasonografic profile in polycystic ovarian syndrome. Hum Reprod 2001; 16: 36–42.
20. Guido M, Romualdi D, Giuliani M et al. Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study. J Clin Endocrinol Metab 2004; 89 (6): 2817–23.
21. Batukan C, Muderis II. Efficacy of a new oral contraceptive containing drospirenone and ethinyl estradiol in the long-term treatment of hirsutism. Fertil Steril 2006; 85 (2): 436–40.
22. Heuser I, Deuschle M, Weber B et al. Increased activity of the hypothalamus-pituitary-adrenal system after treatment with the minralocorticoid receptor antagonist spironolactone. Psychoneuroendocrinology 2000; 25: 513–8.
23. Parsey KS, Pong A. An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen. Contraception 2000; 61: 105–11.
24. Прилепская В.Н., Назарова М.Н. Гормональная контрацепция. В кн.: Серов В.Н., Прилепская В.Н., Овсянникова Т.В. Гинекологическая эндокринология. М.: МЕДпрессинформ, 2004; 381–470.
25. Wild RA. Long-term health consequences of PCOS. Hum Reprod Update 2002; 8: 231–41.
26. Wiegratz I, Kuhl H. Long-cycle treatment with oral contraceptives. Drugs 2004; 64 (21): 1–16.
Авторы
И.В.Кузнецова
Кафедра акушерства и гинекологии №1 (зав. – проф. А.И.Ищенко) лечебного факультета ММА им. И.М.Сеченова
Кафедра акушерства и гинекологии №1 (зав. – проф. А.И.Ищенко) лечебного факультета ММА им. И.М.Сеченова
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.